Literature DB >> 28879608

Response to the letter to the editor of Lambros et al.

William Sterlacci1, Alexandar Tzankov2, Spasenija Savic2.   

Abstract

Year:  2017        PMID： 28879608     DOI： 10.1007/s00428-017-2230-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  4 in total

1.  MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Authors:  William Sterlacci; Michael Fiegl; Mathias Gugger; Lukas Bubendorf; Spasenija Savic; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2017-05-20       Impact factor: 4.064

2.  Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

Authors:  David R Spigel; Martin J Edelman; Kenneth O'Byrne; Luis Paz-Ares; Simonetta Mocci; See Phan; David S Shames; Dustin Smith; Wei Yu; Virginia E Paton; Tony Mok
Journal:  J Clin Oncol       Date:  2016-12-12       Impact factor: 44.544

3.  Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Giorgio Scagliotti; Joachim von Pawel; Silvia Novello; Rodryg Ramlau; Adolfo Favaretto; Fabrice Barlesi; Wallace Akerley; Sergey Orlov; Armando Santoro; David Spigel; Vera Hirsh; Frances A Shepherd; Lecia V Sequist; Alan Sandler; Jeffrey S Ross; Qiang Wang; Reinhard von Roemeling; Dale Shuster; Brian Schwartz
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

4.  MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.

Authors:  Takafumi Kubo; Hiromasa Yamamoto; William W Lockwood; Ilse Valencia; Junichi Soh; Michael Peyton; Masaru Jida; Hiroki Otani; Tetsuya Fujii; Mamoru Ouchida; Nagio Takigawa; Katsuyuki Kiura; Kenji Shimizu; Hiroshi Date; John D Minna; Marileila Varella-Garcia; Wan L Lam; Adi F Gazdar; Shinichi Toyooka
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.